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Aim
During combination antiretroviral therapy, reduction of
HIV-1 RNA levels to less than 50 copies/ml is fre-
quently achieved; however, residual low-level viremia
has been detected using ultrasensitive assays. The source
of persistent viremia is currently unknown: it could arise
from ongoing cycles of replication in a sanctuary site,
long-lived productively infected cells, and/or activation
of viral expression from latently infected cell reservoirs.
This presentation will discuss the characteristics and
probable sources of persistent viremia.
Materials and methods
Insights into the source and dynamics of residual virus
are determined using ultrasensitive assays for: 1) quanti-
fying persistent viremia and 2) sequencing persistent
HIV populations from plasma and cells.
Results
Using sensitive assays it has been shown that HIV per-
sists for at least 7 years of therapy. The decay of persis-
tent viremia in plasma of patients on suppressive
therapy appears to be biphasic with short-lived cells
contributing to the viremia initially followed by a second
more constant release of virus from long-lived HIV-
infected cells. An indicator that current treatment regi-
mens halt ongoing viral replication is that intensifying a
patient’s treatment regimen does not result in a decrease
in persistent viremia. Moreover, persistent viremia in
patients under long-term treatment is genetically homo-
geneous and the viral population which rebounds during
treatment interruption is also genetically homogeneous
Discussion
The genetic homogeneity of the viral populations in
patients on suppressive thereapy indicates that persistent
viremia arises from long-lived latently infected cells,
such as resting memory CD4+ T-cells, tissue CD4+
T-cells, tissue macrophages or stems cells, and reflects
an evolutionary bottleneck during prolonged therapy.
However, it is possible viral production may occur in
such anatomical compartments as the gut or central
nervous system where drug penetration is suboptimal.
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